These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12442681)

  • 1. Strategies to modify levodopa treatment.
    Widner H
    Adv Neurol; 2003; 91():229-36. PubMed ID: 12442681
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medical treatment of L-dopa induced dyskinesia].
    Kuno S
    Nihon Rinsho; 2000 Oct; 58(10):2110-4. PubMed ID: 11068456
    [No Abstract]   [Full Text] [Related]  

  • 3. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 4. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why delaying levodopa is a good treatment strategy in early Parkinson's disease.
    Olanow CW; Stocchi F
    Eur J Neurol; 2000 May; 7 Suppl 1():3-8. PubMed ID: 11054152
    [No Abstract]   [Full Text] [Related]  

  • 6. Deep brain stimulation in Parkinson's disease: opposite effects of stimulation in the pallidum.
    Bejjani BP; Damier P; Arnulf I; Papadopoulos S; Bonnet AM; Vidailhet M; Agid Y; Pidoux B; Cornu P; Dormont D; Marsault C
    Mov Disord; 1998 Nov; 13(6):969-70. PubMed ID: 9827624
    [No Abstract]   [Full Text] [Related]  

  • 7. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 8. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
    Stacy M; Galbreath A
    Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should levodopa be used anymore?
    Zegers de Beyl D
    Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy for patients with progressive Parkinson's disease].
    Murata M
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1432-7. PubMed ID: 13677891
    [No Abstract]   [Full Text] [Related]  

  • 12. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C; Aubert I; Li Q; Gurevich VV; Benovic JL; Ferry S; Mach U; Stark H; Leriche L; Håkansson K; Bioulac BH; Gross CE; Sokoloff P; Fisone G; Gurevich EV; Bloch B; Bezard E
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 15. Rasagiline for motor complications in Parkinson's disease.
    Clarke CE
    Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976
    [No Abstract]   [Full Text] [Related]  

  • 16. The treatment of early Parkinson's disease: levodopa rehabilitated.
    Vlaar A; Hovestadt A; van Laar T; Bloem BR
    Pract Neurol; 2011 Jun; 11(3):145-52. PubMed ID: 21551108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Welcome news about levodopa, but uncertainty remains.
    Fahn S
    Ann Neurol; 1998 May; 43(5):551-4. PubMed ID: 9585348
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms of motor complications in treatment of Parkinson's disease.
    Kumar A; Huang Z; de la Fuente-Fernández R
    Adv Neurol; 2003; 91():193-201. PubMed ID: 12442678
    [No Abstract]   [Full Text] [Related]  

  • 19. [Long-term complications of treatment with levodopa].
    Castro García A; Sesar Ignacio A
    Neurologia; 1998; 13 Suppl 1():41-8. PubMed ID: 9859685
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of levodopa-induced dyskinesia].
    Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.